Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Michèle Voegeli"'
Autor:
Urban Novak, Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Enrico Derenzini, Thilo Zander, Georg Hess, Ulrich Mey, Simone Ferrero, Nicolas Mach, Carola Boccomini, Sebastian Böttcher, Michèle Voegeli, Anne Cairoli, Vanesa-Sindi Ivanova, Thomas Menter, Stefan Dirnhofer, Bernhard Scheibe, Sandra Gadient, Katrin Eckhardt, Emanuele Zucca, Christoph Driessen, Christoph Renner
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102221- (2023)
Summary: Background: The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL). In vitro, their combination p
Externí odkaz:
https://doaj.org/article/2a646da2dfa940a19c0def3d5335b73c
Autor:
Emanuele Zucca, Natalie Fischer, Felicitas Hitz, A Schmidt, C Pfleger, C Caspar, S Güsewell, M. Fehr, M Rütti, Frank Stenner, Michèle Voegeli, Alden A. Moccia, Fatime Krasniqi, Ulrich Mey, Mario Bargetzi, Guido Ghilardi, P Richter, W. Mingrone, N Lang, Thilo Zander, S. Aeppli, D. Brülisauer, M Ebnöther, Urban Novak
Publikováno v:
Hematological Oncology. 39:196-204
Hodgkin lymphoma (HL) in older patients appears to be a different disease compared with younger patients with historically lower survival rates. This is related to a variety of factors, including increased treatment-related toxicity, the presence of
Autor:
Christoph Renner, Georg Hess, Stefan Dirnhofer, Simone Ferrero, Christoph Driessen, Sebastian Böttcher, Urban Novak, G. Scheubeck, Safaa M. Ramadan, Michèle Voegeli, S. Gadient, Thomas Menter, M. Fehr, Ulrich Mey, M. Dreyling, C. Boccomini, N. Mach, Emanuele Zucca, K. Eckhardt, Anne Cairoli, Sämi Schär, Thilo Zander
Publikováno v:
Hematological Oncology. 39
Autor:
D. Brülisauer, Fatime Krasniqi, Mario Bargetzi, Guido Ghilardi, Richard W. Tsang, M Rütti, Vishal Kukreti, Urban Novak, David C. Hodgson, Felicitas Hitz, Ulrich Mey, W. Mingrone, Frank Stenner, Natalie Fischer, S Güsewell, Robert Kridel, A Schmidt, Michèle Voegeli, Anca Prica, N Lang, John Kuruvilla, Danielle Rodin, Thilo Zander, M Ebnöther, Michael Crump, L Rubio, Martin Fehr, P Richter, C Caspar, Stefanie Aeppli, Alden A. Moccia, A.J. Templeton
Publikováno v:
Hematological Oncology. 39
Autor:
Michèle Voegeli, Andreas Wicki
Publikováno v:
Therapeutische Umschau. 75:622-626
Neoadjuvant, adjuvant and palliative systemic therapy of colorectal cancer Abstract. Neoadjuvant therapy is indicated for stage T3 / 4 and all N1 rectal cancers. Usually, chemoradiotherapy with capecitabine or 5FU is applied within a timeframe of 5
Autor:
Erika Lerch, Michele Ghielmini, Jochen Rentschler, Thomas Pabst, Lorenz M. Jost, Stephanie Rondeau, Simona Berardi Vilei, Mario Bargetzi, Luciano Wannesson, Angelika Bischof Delaloye, Michèle Voegeli, Nicolas Ketterer
Publikováno v:
Hematological Oncology. 35:576-583
Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high-dose melphalan, on the other hand, has been shown to be safe and active as a pretransplant preparativ
Autor:
Michèle, Voegeli, Andreas, Wicki
Publikováno v:
Therapeutische Umschau. Revue therapeutique. 75(10)
Neoadjuvant, adjuvant and palliative systemic therapy of colorectal cancer
Autor:
Michèle, Voegeli, Stephanie, Rondeau, Simona, Berardi Vilei, Erika, Lerch, Luciano, Wannesson, Thomas, Pabst, Jochen, Rentschler, Mario, Bargetzi, Lorenz, Jost, Nicolas, Ketterer, Angelika, Bischof Delaloye, Michele, Ghielmini
Publikováno v:
Hematological oncology. 35(4)
Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high-dose melphalan, on the other hand, has been shown to be safe and active as a pretransplant preparativ
Autor:
Stephan Kiss, Fabio Nussberger, Christoph Cantieni, Niels Willi, Michèle Voegeli, Svetozar Subotic, Patrick Maurer, Thomas Gasser
Publikováno v:
Forum Médical Suisse ‒ Swiss Medical Forum. 16
Autor:
Gieri Cathomas, Berenika Willi, Viktor H. Koelzer, Andreas Wicki, Niels Willi, Alfred Zippelius, Kirsten D. Mertz, Deborah Zihler, Sacha I. Rothschild, Michèle Voegeli
Publikováno v:
Journal for Immunotherapy of Cancer
Background Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic melanoma and non-small cell lung c